← Library
Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Pinealon

Not FDA approved

Synthetic tripeptide bioregulator

Also known as: EDR peptide, Glu-Asp-Arg, glutamyl-aspartyl-arginine, L-Glutamyl-L-aspartyl-L-arginine, Pinealon acetate salt form, H-Glu-Asp-Arg-OH, L-Glu-L-Asp-L-Arg

Evidence score
21/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a research chemical, not approved
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Pinealon, also called EDR peptide, is a short synthetic peptide made of three amino acids (glutamic acid, aspartic acid, and arginine). It comes from the Russian 'peptide bioregulator' research tradition, where it is proposed to act on brain cells and possibly influence gene expression and oxidative stress responses. These mechanisms are hypothesized and come largely from cell and animal work.

What the evidence shows

Automatic summaryAnimal / preclinical

There are no registered human clinical trials, and the roughly 17 published papers are mostly laboratory and animal studies, with a few small reports from a single research group. No benefit in humans has been established, and it is not FDA-approved for any use.

Key facts

Molecular formula
C15H26N6O8
Molecular weight
418.4 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

17papers referencing Pinealon

Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.

Biochemistry (Mosc)2011

Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.

Int J Clin Exp Med2012

[Neuroprotective effects of peptides bioregulators in people of various age].

Adv Gerontol2013

Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.

Rejuvenation Res2011

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.